Lexeo Therapeutics (LXEO) Common Equity (2022 - 2026)

Lexeo Therapeutics' Common Equity history runs 5 years deep, the most recent figure standing at $231.5 million for Q1 2026.

• In Q1 2026, Common Equity rose 162.72% year-over-year to $231.5 million; the TTM figure through Mar 2026 stood at $231.5 million (up 162.72% YoY), while the FY2025 annual figure was $246.7 million, up 111.11% from the prior year.
• Common Equity came in at $231.5 million for Q1 2026 at Lexeo Therapeutics, down from $246.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $246.7 million in Q4 2025 to a low of -$162.8 million in Q3 2023.
• A 5-year average of $59.6 million and a median of $116.8 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 64.49% in 2023 and jumped 239.46% in 2024, its largest moves.
• Lexeo Therapeutics' Common Equity stood at -$113.0 million in 2022, then jumped by 200.51% to $113.5 million in 2023, then grew by 2.91% to $116.8 million in 2024, then surged by 111.11% to $246.7 million in 2025, then decreased by 6.15% to $231.5 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $231.5 million, $246.7 million, and $120.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison